ENTOD Pharmaceuticals launched a nationwide glaucoma awareness movement during World Glaucoma Week 2026. The campaign deployed 500+ field experts and teams up with 3,000+ ophthalmologists to strengthen early detection and routine screening, halting the “Silent Thief of Sight.
In India, glaucoma affects over 12 million people, accounting for 12.8% of total blindness, with nearly 90% of cases undiagnosed until advanced stages.
Speaking on the importance of early detection, Dr. J. Ashok, Cataract & Glaucoma Surgeon, Solis Eye care Hospitals Pvt Ltd., Hyderabad, stated, “Glaucoma is particularly dangerous because patients often do not experience symptoms until significant vision loss has already occurred. Once vision is lost due to glaucoma, it cannot be restored. However, with regular eye examinations and timely treatment, disease progression can be effectively controlled. Awareness and routine screening, especially for individuals above 40 years of age and those with a family history, are critical in preventing avoidable blindness.”
Commenting on the nationwide initiative, Nikkhil K. Masurkar, CEO of ENTOD Pharmaceuticals, said, “Preventive healthcare must be at the centre of our national health agenda. Glaucoma does not announce itself; it silently compromises vision over time. Through this movement, we aim to strengthen awareness at the community level and support ophthalmologists in encouraging early screening and responsible eye care practices.”
During the week-long campaign, more than 500 trained field professionals across India worked closely with over 3,000 ophthalmologists to support patient education initiatives. From leading metropolitan eye hospitals to regional and local clinics, the initiative is designed to ensure that discussions around glaucoma screening reach individuals who may otherwise remain unaware of their risk.
By transforming awareness into action, the campaign reinforces a simple but powerful message: early diagnosis can preserve sight and significantly improve long-term quality of life.
